Chan Su Park

Dr. Chan Su Park

Yonsei University, Seoul, Republic of Korea
+1
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 September 2022 in Cancers
Verified
Journal Article
Open access
PDF file
Chan Su ParkChan Su Park
Chan Su Park
MSMin Je Sung
Min Je Sung
SKSo Jeong Kim
So Jeong Kim
JJJung Hyun Jo
Jung Hyun Jo
HLHee Seung Lee
Hee Seung Lee
JPJeong Youp Park
Jeong Youp Park
Some BTC types respond to pembrolizumab, but there are no known prognostic factors to predict its treatment benefits. In this study, we attempted to identify the prognostic factors associated with pembrolizumab as a second-line treatment for gemcitabine-refractory BTC. This retrospective and single tertiary-center study involved all the consecutive patients (n = 80) with refractory advanced BTC, who were diagnosed as programmed cell death ligand 1-positive and treated with pembrolizumab between August 2017 and February 2021. The overall survival (OS) was analyzed using Cox regression analysis. The median OS was 6.0 months [95% confidence interval (CI): 3.87–8.20]; median progression-free survival was 1.9 months (95% CI: 1.82–1.98); and the response rate was 15.9%. In the multivariate Cox regression analysis, the TB [adjusted hazard ratio (HR) = 2.286; 95% CI: 1.177–4.440; p = 0.015), albumin levels (adjusted HR = 0.392; 95% CI: 0.211–0.725; p = 0.003), ALP levels (adjusted HR = 1.938; 95% CI: 1.105–3.400; p = 0.021), and LMR (adjusted HR = 0.325; 95% CI: 0.173–0.609; p < 0.001) were identified as significant variables associated with the OS. High albumin levels and LMR and low ALP levels and TB were significantly associated with better OS in patients treated with pembrolizumab.

2 July 2024 in APL Bioengineering
Verified
Journal Article
Open access
PDF file
Chan Su ParkChan Su Park
Chan Su Park
HPHyun Jin Park
Hyun Jin Park
JPJi Hoon Park
Ji Hoon Park
JLJin Hee Lee
Jin Hee Lee
HKHyun Jung Kee
Hyun Jung Kee
MCMoon Jae Chung
Moon Jae Chung
Duodenal mucosal resurfacing (DMR) by thermal ablation of the duodenal mucosa is a minimally invasive endoscopic procedure for controlling metabolic syndrome (MS). However, thermal energy can cause adverse effects due to deep mucosal injury, necessitating an additional mucosal lifting process, which complicate the procedures. Therefore, we aimed to develop a similar procedure using non-thermal photodynamic therapy (PDT) for DMR using a highly functional metal stent covered with photosensitizers (PSs) to minimize the potential risks of thermal ablation injury. We developed a novel PS stent enabling the controlled release of radical oxygen species with specific structures to prevent stent migration and duodenal stricture after ablation and performed an animal study (n = 8) to demonstrate the feasibility and safety of PDT for DMR. The stents were placed for 7 days to prevent duodenal strictures after PDT. To confirm PDT efficacy, we stained for gastric inhibitory polypeptide (GIP) and glucose transporter isoform 1. The PS stents were deployed, and PDT was applied without evidence of duodenal stricture, pancreatitis, or hemorrhage in any of the pigs. Microscopic evaluation indicated apoptosis of the mucosal cells in the irradiated duodenum on days 7 and 14, which recovered after day 28. Immunohistochemistry revealed suppressed GIP expression in the mucosal wall of the irradiated duodenum. Endoscopic PDT for DMR using PS stents could be applied safely in a porcine model and may result in decreased GIP secretion, which is a crucial mechanism in MS treatment. Further clinical studies are required to explore its safety and efficacy in patients with MS.

10 June 2026 in Gut and Liver
Verified
Journal Article
Open access
PDF file
KSKangju Son
Kangju Son
BPByung Kyu Park
Byung Kyu Park
Chan Su ParkChan Su Park
Chan Su Park
JHJoung-Ho Han
Joung-Ho Han
KLKyong Joo Lee
Kyong Joo Lee
Kangju Son, Byung Kyu Park, Chan Su Park, Joung-Ho Han, Kyong Joo Lee. Gut and Liver -0001;0:. https://doi.org/10.5009/gnl250551